This provider's $4.2M in total Medicare payments ranks in the 96th percentile of Hematology-Oncology providers nationally.
Their average markup ratio of 6.36x is significantly above the specialty median of 3.5x.
AI-generated analysis based on Medicare payment data.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $618.50 | $91.02 | 6.80x | $527.48 | $403.5K | 10.9K | 3.4K |
| 2015 | $740.30 | $113.76 | 6.51x | $626.54 | $413.2K | 12.8K | 3.6K |
| 2016 | $676.35 | $103.41 | 6.54x | $572.94 | $519.4K | 14.9K | 4.4K |
| 2017 | $599.22 | $88.84 | 6.74x | $510.38 | $523.2K | 16.2K | 4.8K |
| 2018 | $701.53 | $106.15 | 6.61x | $595.38 | $589.4K | 15.7K | 5.4K |
| 2019 | $750.89 | $116.16 | 6.46x | $634.73 | $410.6K | 5.3K | 2.0K |
| 2020 | $716.48 | $103.51 | 6.92x | $612.97 | $495.4K | 6.5K | 2.2K |
| 2021 | $855.42 | $84.80 | 10.09x | $770.62 | $412.4K | 6.1K | 1.8K |
| 2022 | $397.90 | $34.44 | 11.55x | $363.46 | $200.4K | 4.4K | 1.4K |
| 2023 | $400.67 | $28.54 | 14.04x | $372.13 | $214.3K | 5.0K | 1.7K |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| J2505 | Injection, pegfilgrastim, 6 mg | 338 | $989.8K | $2.9K | 6.85x |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | 12.4K | $953.5K | $76.68 | 4.59x |
| G9678 | Oncology Care Model service | 3.9K | $615.6K | $157.28 | 1.02x |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | 5.0K | $506.8K | $101.35 | 6.34x |
| J9310 | Injection, rituximab, 100 mg | 217 | $131.1K | $604.21 | 6.02x |
| 80047 | Blood test, basic group of blood chemicals | 9.6K | $97.2K | $10.16 | 18.70x |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | 11.2K | $95.3K | $8.52 | 7.16x |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | 9.2K | $93.1K | $10.09 | 7.50x |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | 3.7K | $51.7K | $14.14 | 16.54x |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | 971 | $48.7K | $50.18 | 8.33x |
| 96417 | Infusion of different chemotherapy drug or substance into a vein up to 1 hour | 925 | $45.1K | $48.77 | 11.74x |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | 3.0K | $41.4K | $13.92 | 11.23x |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | 328 | $39.0K | $118.82 | 4.64x |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | 680 | $38.6K | $56.69 | 9.98x |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | 689 | $33.8K | $49.04 | 4.67x |
| 36415 | Insertion of needle into vein for collection of blood sample | 10.5K | $31.2K | $2.97 | 11.41x |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | 278 | $30.0K | $108.08 | 4.47x |
| J9271 | Injection, pembrolizumab, 1 mg | 657 | $27.4K | $41.68 | 5.95x |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | 145 | $22.9K | $157.59 | 5.99x |
| 96415 | Infusion of chemotherapy into a vein | 922 | $20.0K | $21.67 | 26.50x |
This provider submits charges 6.36 times higher than what Medicare actually pays.
A markup ratio of 6.36x means for every $100 Medicare pays, this provider initially charges $636. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data